Pasadena-based venture capital firm California Technology Ventures has scored an exit at one of its portfolio firms, selling cardiac catheter maker AngioScore, to medical device firm Spectranetics. Spectranetics said it would pay $230M plus earnout for AngioScore, which was backed by California Technology Ventures, Innomed Ventures, Linkagene LP, Pelion Ventures, Psilos Group Management, QuestMark Partners, Saints Capital and Telegraph Hill Partners. California Technology Ventures has been an investor in AngioScore since at least 2004, as part of the company's Series B funding.
Top NewsWednesday, May 28, 2014
California Technology Ventures Gets Exit An AngioScore